Information letter to health care professionals regarding the medicinal product BENTERO (bendamustine). Bendamustine: increased mortality when used in unapproved combination treatment regimens or outside approved indications

29.04.2026 256 views

Інформаційний лист-звернення до спеціалістів системи охорони здоров’я щодо лікарського засобу БЕНТЕРО (бендамустин). Бендамустин: підвищення рівня смертності при застосуванні в незатверджених комбінованих схемах лікування або поза затвердженими показаннямиPDF · 160 КБ

Завантажити

Information letter to health care professionals regarding the medicinal product BENTERO (bendamustine). Bendamustine: increased mortality when used in unapproved combination treatment regimens or outside approved indications

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Information letter to health care professionals regarding the medicinal product BENTERO (bendamustine). Bendamustine: increased mortality when used in unapproved combination treatment regimens or outside approved indications

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration